Ballentine Partners LLC Increases Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Ballentine Partners LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,941 shares of the medical equipment provider’s stock after purchasing an additional 273 shares during the period. Ballentine Partners LLC’s holdings in Hologic were worth $307,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Hologic during the 4th quarter valued at about $27,000. Massmutual Trust Co. FSB ADV raised its position in Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock worth $40,000 after acquiring an additional 227 shares during the period. Allworth Financial LP boosted its stake in shares of Hologic by 39.3% during the 4th quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after acquiring an additional 179 shares during the last quarter. Mather Group LLC. purchased a new position in shares of Hologic during the 1st quarter worth $48,000. Finally, Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Hologic by 145.3% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 468 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Argus lifted their target price on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Friday, May 3rd. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Finally, Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and lifted their target price for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $85.60.

Hologic Stock Down 1.1 %

Shares of HOLX stock opened at $71.65 on Wednesday. The company’s fifty day simple moving average is $74.42 and its two-hundred day simple moving average is $74.25. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $82.45. The stock has a market cap of $16.72 billion, a P/E ratio of 36.56, a PEG ratio of 2.43 and a beta of 1.00. The company has a quick ratio of 3.29, a current ratio of 3.97 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter last year, the business posted $1.06 EPS. Analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.